A glycine- and leucine-based tripeptide improves symptoms in a mouse model of nonalcoholic fatty liver disease, which lacks approved treatments.
No takes yet. Share an insight, caveat, or question.
Rom et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: